Effectiveness and Safety of Adjunctive Traditional Chinese Medicine Therapy for Primary Liver Cancer Patients: A Protocol for Systematic Review and Meta Analysis

Overview

Journal Medicine (Baltimore)

Specialty General Medicine

Date 2020 Aug 7

PMID 32756108

Citations 4

Authors

Tingting Li

Xiaona Zhang

Shanshan Xu

Hongjie Cheng

Hong Zhang

Affiliations

Soon will be listed here.

Abstract

Background: Traditional Chinese medicine (TCM) has gradually drawn the attention of clinicians as an alternative for Primary Liver Cancer (PLC), is based on the theory of syndrome differentiation. However, owing to the lack of evidence-based medical evidence, the authors designed this protocol to evaluate TCM's effectiveness and safety.

Methods: Seven electronic databases will be searched from inception to Aug. 2020. Two of us will independently identify randomized controlled trials, extract the data and assess the risk of bias. The meta-analysis will be conducted with the Review Manager 5.3 software according the heterogeneity of eligible studies. Further, we will use the grading of recommendations assessment, development, and evaluation to evaluate the evidence quality.

Results: This study will demonstrate an evidence-based review of TCM for PLC.

Conclusion: The study will provide clear evidence to assess the effectiveness and side effects of TCM for PLC.

Trial Registration Number: PROSPERO CRD 42020173748.

Citing Articles

inhibits the growth and metastasis of liver cancer by downregulating miR-9-5p and upregulating PDK4.

Si T, Huang L, Liang T, Huang P, Zhang H, Zhang M Cancer Biol Ther. 2023; 24(1):2246198.

PMID: 37773732 PMC: 10543352. DOI: 10.1080/15384047.2023.2246198.

Combining the Anticancer and Immunomodulatory Effects of and Shiitake as an Integrated Therapeutic Approach.

Balakrishnan B, Liang Q, Fenix K, Tamang B, Hauben E, Ma L Nutrients. 2021; 13(8).

PMID: 34444724 PMC: 8401741. DOI: 10.3390/nu13082564.

Clinical Effect of Iodine-125 Seed Implantation in Patients with Primary Liver Cancer and Its Effect on Th1/Th2 Cells in Peripheral Blood.

Chen X, Zhu F, Wang B, Zhou Y, Xiong H, Fan T J Oncol. 2021; 2021:6199732.

PMID: 34367285 PMC: 8342174. DOI: 10.1155/2021/6199732.

Transcatheter hepatic arterial chemoembolization combined with Kangai injection for hepatitis B virus-related hepatocellular carcinoma: A protocol for a PRISMA-compliant meta-analysis.

Wang W, Wang S, Liu J, Liu Y, Mu Y, Wang J Medicine (Baltimore). 2020; 99(41):e22565.

PMID: 33031303 PMC: 10545312. DOI: 10.1097/MD.0000000000022565.

References

Guan C, Cai L, Yue L, Zhang Y . [Clinicel study on treatment of advanced primary liver cancer by Yanshu injection combining with chemotherapy]. Zhongguo Zhong Yao Za Zhi. 2006; 31(6):510-2. View

Pircher A, Medinger M, Drevs J . Liver cancer: Targeted future options. World J Hepatol. 2011; 3(2):38-44. PMC: 3060418. DOI: 10.4254/wjh.v3.i2.38. View

Hu Y, Li L, Gong S . [Regulatory effect of astragalus injection on Th1/Th2 cell function in patients with cervical cancer]. Zhongguo Zhong Xi Yi Jie He Za Zhi. 2011; 30(11):1157-9. View

Wang J, Jin Y, Xu Z, Zheng Z, Wan S . Involvement of caspase-3 activity and survivin downregulation in cinobufocini-induced apoptosis in A 549 cells. Exp Biol Med (Maywood). 2009; 234(5):566-72. DOI: 10.3181/0811-RM-326. View

Hutton B, Salanti G, Caldwell D, Chaimani A, Schmid C, Cameron C . The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Ann Intern Med. 2015; 162(11):777-84. DOI: 10.7326/M14-2385. View

Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M . Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev. 2015; 4:1. PMC: 4320440. DOI: 10.1186/2046-4053-4-1. View

El-Serag H . Hepatocellular carcinoma. N Engl J Med. 2011; 365(12):1118-27. DOI: 10.1056/NEJMra1001683. View

Jiang M, Lu C, Zhang C, Yang J, Tan Y, Lu A . Syndrome differentiation in modern research of traditional Chinese medicine. J Ethnopharmacol. 2012; 140(3):634-42. DOI: 10.1016/j.jep.2012.01.033. View

Higgins J, Thompson S, Deeks J, Altman D . Measuring inconsistency in meta-analyses. BMJ. 2003; 327(7414):557-60. PMC: 192859. DOI: 10.1136/bmj.327.7414.557. View

10.

Zhou J, Yu L, Gao X, Hu J, Wang J, Dai Z . Plasma microRNA panel to diagnose hepatitis B virus-related hepatocellular carcinoma. J Clin Oncol. 2011; 29(36):4781-8. DOI: 10.1200/JCO.2011.38.2697. View

11.

Andrews J, Guyatt G, Oxman A, Alderson P, Dahm P, Falck-Ytter Y . GRADE guidelines: 14. Going from evidence to recommendations: the significance and presentation of recommendations. J Clin Epidemiol. 2013; 66(7):719-25. DOI: 10.1016/j.jclinepi.2012.03.013. View

12.

Chen H, Chen Z . [Transcatheter arterial chemoembolization combined with other therapies for the treatment of primary hepatic carcinoma: a review]. Zhong Xi Yi Jie He Xue Bao. 2008; 6(4):422-6. DOI: 10.3736/jcim20080419. View

13.

Liu L, Chen B, Qin S . [Anti-angiogenesis effect of arsenic trioxide plus cinobufacin on human hepatocarcinoma transplantation model nude mice]. Zhongguo Zhong Xi Yi Jie He Za Zhi. 2011; 31(1):67-72. View